Skip to main content
SpringerLink
Log in

Lysosomal Storage Disorders

  • Chapter
Lysosomes

Part of the book series: Medical Intelligence Unit ((MIUN))

Abstract

The lysosomal storage disorders (LSD) are a group of about 50 diseases that are characterised by an accumulation of waste products in the lysosomes, resulting in the formation of large intracellular vacuoles (Fig. 1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. De Duve C. Lysosomes, a new group of cytoplasmic particles. In: Hayashi T, ed. Subcellular Particles. Ronald Press, 1959:128–159.

    Google Scholar 

  2. Meikle PJ, Hopwood JJ, Clague AE et al. Prevalence of lysosomal storage disorders. JAMA 1999; 281(3):249–54.

    Article  PubMed  CAS  Google Scholar 

  3. Poorthuis BJ, Wevers RA, Kleijer WJ et al. The frequency of lysosomal storage diseases in the Netherlands. Hum Gen 1999; 105:151–156.

    CAS  Google Scholar 

  4. Raychowdhury MK, Gonzalez-Perrett S, Montalbetti N et al. Molecular pathophysiology of mucolipidosis type IV: pH dysregulation of the mucolipin-1 cation channel. Hum Mol Genet 2004; 13(6):617–27.

    Article  PubMed  CAS  Google Scholar 

  5. Masson C, Cisse I, Simon V et al. Fabry disease: A review. Joint Bone Spine 2004; 71(5):381–3.

    Article  PubMed  Google Scholar 

  6. Hopwood JJ, Bunge S, Morris CP et al. Molecular basis of mucopolysaccharidosis type II: Mutations in the iduronate-2-sulphatase gene. Hum Mutat 1993; 2(6):435–42.

    Article  PubMed  CAS  Google Scholar 

  7. Nishino I, Fu J, Tanji K et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000; 406(6798):906–10.

    Article  PubMed  CAS  Google Scholar 

  8. Ikonen E, Peltonen L. Mutations causing aspartylglucosaminuria (AGU): a lysosomal accumulation disease. Hum Mutat 1992:1(5):361–5.

    Article  PubMed  CAS  Google Scholar 

  9. Varho TT, Alajoki LE, Posti KM et al. Phenotypic spectrum of Salla disease, a free sialic acid storage disorder. Pediatr Neurol 2002; 26(4):267–73.

    Article  PubMed  Google Scholar 

  10. Horowitz M, Pasmanik-Chor M, Borochowitz Z et al. Prevalence of glucocerebrosidase mutations in the israeli ashkenazi Jewish population. Hum Mutat 1998; 12(4):240–4.

    Article  PubMed  CAS  Google Scholar 

  11. Myerowitz R. Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene. Hum Mutat 1997; 9(3):195–208.

    Article  PubMed  CAS  Google Scholar 

  12. Beutler E, Grabowski GA. Gaucher disease. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3635–3668.

    Google Scholar 

  13. Gravel RA, Kaback MM, Proia RL et al. The GM2 Ganglisiodosis. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3827–3876.

    Google Scholar 

  14. Hirshhorn R, Reuser A. Glycogen storage disease type II: Acid alpha-glucosidase (acid maltase) deficiency. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3389–3420.

    Google Scholar 

  15. Beta-galactosidase deficiency (beta-galactosidosis). In: Suzuki Y, Oshima A, Nanba E, Schriver CR, Beaudet AL, Sly WS, Valle D, eds. GM1 gangliosidosis and Morquio B disease. 2001:3775–3809.

    Google Scholar 

  16. Patterson JS, Jones MZ, Lovell KL et al. Neuropathology of bovine beta-mannosidosis. J Neuropathol Exp Neurol 1991; 50(5):538–46.

    Article  PubMed  CAS  Google Scholar 

  17. Boyer PJ, Jones MZ, Rathke EJ et al. Regional central nervous system oligosaccharide storage in caprine beta-mannosidosis. J Neurochem 1990; 55(2):660–4.

    Article  PubMed  CAS  Google Scholar 

  18. Bedilu R, Nummy KA, Cooper A et al. Variable clinical presentation of lysosomal beta-mannosidosis in patients with null mutations. Mol Genet Metab 2002; 77(4):282–90.

    Article  PubMed  CAS  Google Scholar 

  19. Bijsterbosch MK, Donker W, van de Bilt H et al. Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. Eur J Biochem 1996; 237(2):344–9.

    Article  PubMed  CAS  Google Scholar 

  20. Zhu Y, Li X, Kyazike J et al. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in Pompe mice. J Biol Chem 2004, [Epub ahead of print].

    Google Scholar 

  21. Whittington R, Goa KL. Alglucerase. A review of its therapeutic use in Gaucher’s disease. Drugs 1992; 44(1):72–93.

    Article  PubMed  CAS  Google Scholar 

  22. Grabowski GA, Barton NW, Pastores G et al. Enzyme therapy in type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995; 122:33–39.

    PubMed  CAS  Google Scholar 

  23. Mignani R, Cagnoli L. Enzyme replacement therapy in Fabry’s disease: Recent advances and clinical applications. J Nephrol 2004; 17(3):354–63.

    PubMed  CAS  Google Scholar 

  24. Wraith JE, Clarke LA, Beck M et al. Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004; 144(5):581–8.

    Article  PubMed  CAS  Google Scholar 

  25. Van den Hout JM, Kamphoven JH, Winkel LP et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004; 113(5):e448–57.

    Article  PubMed  Google Scholar 

  26. Lachmann RH. alpha-glucosidase (CHO) (Genzyme). Curr Opin Investig Drugs 2004; 5(10):1101–10.

    PubMed  CAS  Google Scholar 

  27. Muenzer J, Lamsa JC, Garcia A et al. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): A preliminary report. Acta Paediatr Suppl 2002; 91(439):98–9.

    Article  PubMed  CAS  Google Scholar 

  28. Harmatz P, Whitley CB, Waber L et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004; 144(5):574–80.

    Article  PubMed  CAS  Google Scholar 

  29. Bae JS, Jang KH, Schuchman TR et al. Comparative effects of recombinant acid sphingomyelinase administration by different routes in niemann-pick disease mice. Exp Anim 2004; 53(5):417–21.

    Article  PubMed  CAS  Google Scholar 

  30. Roces DP, Lullmann-Rauch R, Peng J et al. Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: A preclinical animal study. Hum Mol Genet 2004; 13(18):1979–88.

    Article  PubMed  CAS  Google Scholar 

  31. Hoogerbrugge PM, Brouwer OF, Bordigoni P et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet 1995; 345(8962):1398–402.

    Article  PubMed  CAS  Google Scholar 

  32. Zheng Y, Rozengurt N, Ryazantsev S et al. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Mol Genet Metab 2003; 79(4):233–44.

    Article  PubMed  CAS  Google Scholar 

  33. Barranger JM, Novelli EA. Gene therapy for lysosomal storage disorders. Expert Opin Biol Ther 2001; 1(5):857–67.

    Article  PubMed  CAS  Google Scholar 

  34. Mandel RJ, Burger C. Clinical trials in neurological disorders using AAV vectors: Promises and challenges. Curr Opin Mol Ther 2004; 6(5):482–90.

    PubMed  CAS  Google Scholar 

  35. Elstein D, Hollak C, Aerts JM et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004; 27(6):757–66.

    Article  PubMed  CAS  Google Scholar 

  36. Meikle PJ, Ranieri E, Simonsen H et al. Newborn screening for lysosomal storage disorders: Clinical evaluation of a two-tier strategy. Pediatrics 2004; 114(4):909–16.

    Article  PubMed  Google Scholar 

  37. Aronson NN, Kuranda MJ. Lysosomal degradation of Asn-linked glycoproteins. FASEB J 1989; 3:2615–2622.

    PubMed  CAS  Google Scholar 

  38. Thomas G. Disorders of glycoprotein degradation: alpha-mannosidosis, beta-Mannosidosis, Fucosidosis and Sialidosis. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3507–3534.

    Google Scholar 

  39. Desnick RJ, Schindler L. Alpha-N-acetylgalactosaminidase deficiency: Schindler disease. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3483–3506.

    Google Scholar 

  40. Sakuraba H, Matsuzawa F, Aikawa S et al. Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease). J Hum Genet 2004; 49:1–8.

    Article  PubMed  CAS  Google Scholar 

  41. d’Azzo A, Andria G, Strisiugli P et al. Galactosialidosis. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001; 3811–3826.

    Google Scholar 

  42. Aula P, Jalanko A, Peltonen L. Aspartylglucosaminuria. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3535–3550.

    Google Scholar 

  43. von Figura K, Gieselman V, Jaeken J. Metachromatic leukodystrophy. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3695–3724.

    Google Scholar 

  44. Sonnino S, Chigorno V. Ganglioside molecular species containing C18-and C20-sphingosine in mammalian nervous tissues and neuronal cell cultures. Biochim Biophys Acta 2000; 1469:63–77.

    PubMed  CAS  Google Scholar 

  45. Coetzee T, Suzuki K, Popko B. New perspectives on the function of myelin galactolipids. Trends Neurosci 1998; 21:126–130.

    Article  PubMed  CAS  Google Scholar 

  46. Desnick RJ, Ioannou YA, Eng CM. alpha-Galactosidase A deficiency; Fabry Disease. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3507–3534.

    Google Scholar 

  47. Wenger DA, Suzuki K, Suzuki Y et al. Galactosylceramide lipidosis: Globoid cell leukodystrophy (Krabbe disease). In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3669–3694.

    Google Scholar 

  48. Dierks T, Schmidt B, Borissenko LV et al. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell 2003; 113(4):435–44.

    Article  PubMed  CAS  Google Scholar 

  49. Neufeld E, Muenzer J. The Mucopolysaccharidoses. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3669–3694.

    Google Scholar 

  50. Schuchman EH, Desnick RJ. Niemann-Pick Disease Types A and B: Acid sphingomyelinase Deficiencies. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3589–3610.

    Google Scholar 

  51. Moser HW, Linke T, Fensom AH et al. Acid ceramidase deficiency: Farber lipogranulomatosis. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3573–3588.

    Google Scholar 

  52. Assmann G, Seedorf U. Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3551–3572.

    Google Scholar 

  53. Gelb BD, Bromme D, Desnick RJ. Pycnodysostosis: Cathepsin K deficiency In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3453–3468.

    Google Scholar 

  54. Hofmann SJ, Peltonen L. The neuronal ceroid lipofuscinoses. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3877–3896.

    Google Scholar 

  55. Kopan S, Sivasubramaniam U, Warburton MJ. The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: Evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis. Biochem Biophys Res Commun 2004; 319(1):58–65.

    Article  PubMed  CAS  Google Scholar 

  56. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004; 16(1):76–81.

    Article  PubMed  CAS  Google Scholar 

  57. Aula P, Gahl WA. Disorders of free sialic acid storage. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:5109–5120.

    Google Scholar 

  58. Gahl WA, Thoene JG, Schneider JA. Cystinosis: A disorder of lysosomal memmbrane transport. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:5085–5108.

    Google Scholar 

  59. Raas-Rothschild A, Cormier-Daire V, Bao M et al. Molecular basis of variant pseudo-hurler polydystrophy (mucolipidosis IIIC). J Clin Invest 2000; 105(5):673–81.

    Article  PubMed  CAS  Google Scholar 

  60. Kornfeld S, Sly WS. I-Cell Disease and pseudo-hurler polydystrophy: Disorders of lysosomal enzyme phosphorylation and localization. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Meta-bolic and Molecular Bases of Inherited Disease. 2001:3469–3482.

    Google Scholar 

  61. Bach G. Mucolipidosis type IV. Mol Genet Metab 2001:73(3):197–203.

    Article  PubMed  CAS  Google Scholar 

  62. Nishino I. Autophagic vacuolar myopathies. Curr Neurol Neurosci Rep 2003; 3(1):64–9.

    Article  PubMed  Google Scholar 

  63. Nishino I, Fu J, Tanji K et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000; 406(6798):906–10.

    Article  PubMed  CAS  Google Scholar 

  64. Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: Emerging functions for lysosomal membrane proteins. Trends Cell Biol 2003; 13(3):137–45.

    Article  PubMed  CAS  Google Scholar 

  65. Patterson MC, Vanier MT, Suzuki K et al. Niemann-pick disease type c: A lipid trafficking disorder. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3611–3634.

    Google Scholar 

  66. Sturley SL, Patterson MC, Balch W et al. The pathophysiology and mechanisms of NP-C disease. Biochim Biophys Acta 2004; 1685(1–3):83–7.

    PubMed  CAS  Google Scholar 

  67. Hofman SL, Peltonen L. The neuronal ceroid lipofuscinoses In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3877–3896.

    Google Scholar 

  68. Luiro K, Yliannala K, Ahtiainen L et al. Interconnections of CLN3, Hookl and Rab proteins link Batten disease to defects in the endocytic pathway. Hum Mol Genet 2004; 13(23):3017–27.

    Article  PubMed  CAS  Google Scholar 

  69. Mole SE, Michaux G, Codlin S et al. CLN6, which is associated with a lysosomal storage disease, is an endoplasmic reticulum protein. Exp Cell Res 2004; 298(2):399–406.

    Article  PubMed  CAS  Google Scholar 

  70. Winter E, Ponting CP. TRAM, LAG1 and CLN8: Members of a novel family of lipid-sensing domains? Trends Biochem Sci 2004; 27(8):381–3.

    Article  Google Scholar 

  71. Stinchcombe J, Bossi G, Griffiths GM. Linking albinism and immunity: The secrets of secretory lysosomes. Science 2004; 305(5680):55–9.

    Article  PubMed  CAS  Google Scholar 

  72. Huizing M, Gahl WA. Disorders of vesicles of lysosomal lineage: The Hermansky-Pudlak syndromes. Curr Mol Med 2002; 2(5):451–67.

    Article  PubMed  CAS  Google Scholar 

  73. Triggs-Raine B, Salo TJ, Zhang H et al. Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Proc Natl Acad Sci 1999; 96:6296–300.

    Article  PubMed  CAS  Google Scholar 

  74. Tomita Y, Suzuki T. Genetics of pigmentary disorders. Am J Med Genet 2004; 131C(1):75–81.

    Article  Google Scholar 

  75. Clark RH, Stinchcombe JC, Day A et al. Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol 2003; 4(11):1111–20, Epub 2003.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biochemistry, Institute of Medical Biology, University of Tromso, 9037, Tromso, Norway

    Ole Kristian Greiner-Tollersrud & Thomas Berg

Authors
  1. Ole Kristian Greiner-Tollersrud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Eurekah.com and Springer Science+Business Media

About this chapter

Cite this chapter

Greiner-Tollersrud, O.K., Berg, T. (2005). Lysosomal Storage Disorders. In: Lysosomes. Medical Intelligence Unit. Springer, Boston, MA. https://doi.org/10.1007/0-387-28957-7_6

Download citation

Publish with us

Policies and ethics

Search

Navigation